Recombinant VEGF (Ranibizumab Biosimilar) anticorps

N° du produit ABIN7200657

L’anticorps Souris Monoclonal anti-VEGF (Ranibizumab Biosimilar) a été validé pour FACS et in vivo. Il convient pour détecter VEGF (Ranibizumab Biosimilar) dans des échantillons de Humain.

Aperçu rapide pour Recombinant VEGF (Ranibizumab Biosimilar) anticorps (ABIN7200657)

Antigène: VEGF (Ranibizumab Biosimilar)

Type d'anticorp: Recombinant Antibody

Fragment: Fab fragment

Reactivité: Humain

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Cet anticorp VEGF (Ranibizumab Biosimilar) est non-conjugé

Application: Flow Cytometry (FACS), In vivo Studies (in vivo)

Détail du produit anti-VEGF (Ranibizumab Biosimilar) anticorps

Fonction: Ranibizumab Biosimilar, Human VEGF Monoclonal Antibody Fragment (Fab)

Specificité: The Fab protein ranibizumab specifically binds to the human VEGF-A.

Attributs du produit: Recombinant Humanized Monoclonal Antibody Fragment (Fab) generated from the same parent mouse antibody as bevacizumab.

Purification: Protein A affinity column

Pureté: > 95% by SDS-PAGE under reducing conditions and HPLC.

Stérilité: 0.2 μm filtered

niveau d'endotoxine: < 1 EU per 1 mg of the protein by the LAL method.

Immunogène: The research grade Fab protein ranibizumab was produced in the ranibizumab biosimilar E.coli cell line.

Information d'application

Indications d'application: Functional assay, neutralization.

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: 1 mg/mL

Buffer: PBS, pH 7.4, no stabilizers or preservatives.

Agent conservateur: Without preservative

Conseil sur la manipulation: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

Stock: -20 °C

Stockage commentaire: 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.

Date de péremption: 12 months

Détails sur VEGF (Ranibizumab Biosimilar)

Antigène: VEGF (Ranibizumab Biosimilar)

Classe de substances: Biosimilar

Sujet: The humanized anti-VEGF-A monoclonal antibody drug Bevacizumab (trade name Avastin, Genentech/Roche) is the first clinically available angiogenesis inhibitor in the United States. The humanized anti-VEGF-A monoclonal antibody fragment (Fab) Ranibizumab (trade name Lucentis, Genentech) is derived from the same parent mouse antibody as bevacizumab. Both antibody drugs produce angiogenesis inhibition and slow the growth of new blood vessels. Ranibizumab is much smaller than the parent complete antibody but shows stronger binding to VEGF-A after affinity maturation. Ranibizumab can also be used to treat the "wet" type of age-related macular degeneration (AMD, also ARMD), a common form of age-related vision loss.

Vascular endothelial growth factor A (VEGF-A) stimulates angiogenesis in a variety of cancers, including colorectal, lung, breast, glioblastoma, kidney, and ovarian cancers.